NCT00060554WithdrawnPhase 2
A Safety and Efficacy Trial Evaluating the Use of Fondaparinux in Percutaneous Coronary Intervention (PCI)(63133)(WITHDRAWN)
Schering-Plough52 sites in 3 countries300 target enrollmentStarted: April 1, 2003Last updated:
Conditions
Drugs
Trial Snapshot
- Phase
- Phase 2
- Status
- Withdrawn
- Sponsor
- Enrollment
- 300
- Locations
- 52
Study Overview
Brief Summary
The purpose of this research study is to obtain experience in the use of fondaparinux (Arixtra) as compared to heparin when administered to patients who undergo percutaneous coronary intervention (PCI). PCI is a mechanical procedure used to widen the narrowing in a coronary artery in patients with symptomatic coronary artery disease. Fondaparinux and heparin are drugs that inhibit blood clotting.
Study Design
- Study Type
- Interventional
- Allocation
- Randomized
- Intervention Model
- Parallel
- Primary Purpose
- Treatment
- Masking
- Double
Eligibility Criteria
- Ages
- 21 Years to — (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •Scheduled for PCI, including PCI for non-ST elevation acute coronary syndromes (ACS), primary PCI for ST elevation myocardial infarction (MI) or elective PCI (with planned overnight stay in hospital). (Patients undergoing diagnostic heart catherization who are suitable candidates for "ad hoc" PCI are also eligible).
Exclusion Criteria
- •Age < 21 years
- •Activated Clotting Time (ACT) > 200 seconds immediately prior to PCI
- •Use of low molecular weight heparin (LMWH) in the previous 6 hours before PCI
- •Currently receiving an oral anticoagulant (OAC) agent with an INR > 1.8
- •Thrombolytic therapy for ST elevation MI in the previous 24 hours before PCI
- •Active internal bleeding or history of hemorrhagic diathesis
- •Thrombocytopenia (platelet count < 100 x 10-9/L)
- •Pregnant women or women of childbearing potential who are not using an effective method of contraception
- •Known allergy to unfractionated heparin, fondaparinux, aspirin or clopidogrel
- •Absolute contra-indication to anticoagulation
- •Participation in other clinical research studies involving the evaluation of other investigational drugs or devices within 30 days of enrollment or prior participation in this study.
Investigators
Study Sites (52)
Loading locations...
Similar Trials
Completed
Not Applicable
Special Drug Use Investigation for ARIXTRA (Fondaparinux) Abdominal General SurgeryCardiovascular DiseaseNCT01390896GlaxoSmithKline329
Completed
Not Applicable
Special Drug Use Investigation for ARIXTRA (Fondaparinux) Abdominal (Urology,Obstetrics,Gynecology)Cardiovascular DiseaseNCT01390883GlaxoSmithKline475
Terminated
Phase 2
Fondaparinux for the Treatment of Heparin-Induced Thrombocytopenia (HIT)Heparin-Induced ThrombocytopeniaNCT00673439University of Louisville3
Terminated
Not Applicable
Fondaparinux as an Anticoagulant in Haemofiltration in Patients With Acute Kidney Failure.Renal FailureNCT00256100Melbourne Health20
Completed
Phase 3
A Study to Evaluate the Efficacy and Safety of Fondaparinux for the Prevention of Venous Blood Clots in Patients With a Plaster Cast or Other Type of Immobilization for a Below-knee Injury Not Needing SurgeryThrombosis, VenousNCT00843492GlaxoSmithKline1,351